BridgeMD
New treatment option for Pulmonary Aspiration
Official title Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
ClinicalTrials.gov ID: NCT06654219
What this study is testing
- What it's testing
- The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
- Undergoing upper endoscopy only - no colonoscopy due to prep
You likely can't join if
- Previous gastric resection or bypass
- Gastric band in situ
- Previous fundoplication
- Large hiatal hernia
- Pregnant patients
- Recent trauma
See the full eligibility criteria
- Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
- Undergoing upper endoscopy only - no colonoscopy due to prep
- Previous gastric resection or bypass
- Gastric band in situ
- Previous fundoplication
- Large hiatal hernia
- Pregnant patients
- Recent trauma
- Inability to turn to the right lateral decubitus position.
- Patients on erythromycin, metoclopramide, domperidone, opioids.
- Gastroparesis previous
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.